RN7SL563P

Across TCGA pan-cancer cohorts, RN7SL563P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RN7SL563P’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where RN7SL563P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL563P is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

PRAD and THCA are the cancer types where RN7SL563P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL563P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.096	.030	2	view →
THCA	Female	All	−0.084	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

RN7SL563P–PRAD

Open the PRAD breakdown →